216 related articles for article (PubMed ID: 38413223)
1. Targeting the activated microenvironment with endosialin (CD248)-directed CAR-T cells ablates perivascular cells to impair tumor growth and metastasis.
Ash SL; Orha R; Mole H; Dinesh-Kumar M; Lee SP; Turrell FK; Isacke CM
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38413223
[TBL] [Abstract][Full Text] [Related]
2. Endosialin-Expressing Pericytes Promote Metastatic Dissemination.
Viski C; König C; Kijewska M; Mogler C; Isacke CM; Augustin HG
Cancer Res; 2016 Sep; 76(18):5313-25. PubMed ID: 27635044
[TBL] [Abstract][Full Text] [Related]
3. Endosialin in Cancer: Expression Patterns, Mechanistic Insights, and Therapeutic Approaches.
Lu S; Gan L; Lu T; Zhang K; Zhang J; Wu X; Han D; Xu C; Liu S; Yang F; Qin W; Wen W
Theranostics; 2024; 14(1):379-391. PubMed ID: 38164138
[TBL] [Abstract][Full Text] [Related]
4. Endosialin/TEM 1/CD248 is a pericyte marker of embryonic and tumor neovascularization.
Bagley RG; Honma N; Weber W; Boutin P; Rouleau C; Shankara S; Kataoka S; Ishida I; Roberts BL; Teicher BA
Microvasc Res; 2008 Nov; 76(3):180-8. PubMed ID: 18761022
[TBL] [Abstract][Full Text] [Related]
5. Novel banana lectin CAR-T cells to target pancreatic tumors and tumor-associated stroma.
McKenna MK; Ozcan A; Brenner D; Watanabe N; Legendre M; Thomas DG; Ashwood C; Cummings RD; Bonifant C; Markovitz DM; Brenner MK
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36653070
[TBL] [Abstract][Full Text] [Related]
6. Targeting the extra domain A of fibronectin for cancer therapy with CAR-T cells.
Martín-Otal C; Lasarte-Cia A; Serrano D; Casares N; Conde E; Navarro F; Sánchez-Moreno I; Gorraiz M; Sarrión P; Calvo A; De Andrea CE; Echeveste J; Vilas A; Rodriguez-Madoz JR; San Miguel J; Prosper F; Hervas-Stubbs S; Lasarte JJ; Lozano T
J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 35918123
[TBL] [Abstract][Full Text] [Related]
7. Single CAR-T cell treatment controls disseminated ovarian cancer in a syngeneic mouse model.
Ranoa DRE; Sharma P; Schane CP; Lewis AN; Valdez E; Marada VVVR; Hager MV; Montgomery W; Wolf SP; Schreiber K; Schreiber H; Bailey K; Fan TM; Hergenrother PJ; Roy EJ; Kranz DM
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37258040
[TBL] [Abstract][Full Text] [Related]
8. Targeting endosialin/CD248 through antibody-mediated internalization results in impaired pericyte maturation and dysfunctional tumor microvasculature.
Rybinski K; Imtiyaz HZ; Mittica B; Drozdowski B; Fulmer J; Furuuchi K; Fernando S; Henry M; Chao Q; Kline B; Albone E; Wustner J; Lin J; Nicolaides NC; Grasso L; Zhou Y
Oncotarget; 2015 Sep; 6(28):25429-40. PubMed ID: 26327620
[TBL] [Abstract][Full Text] [Related]
9. The stromal cell antigen CD248 (endosialin) is expressed on naive CD8+ human T cells and regulates proliferation.
Hardie DL; Baldwin MJ; Naylor A; Haworth OJ; Hou TZ; Lax S; Curnow SJ; Willcox N; MacFadyen J; Isacke CM; Buckley CD
Immunology; 2011 Jul; 133(3):288-95. PubMed ID: 21466550
[TBL] [Abstract][Full Text] [Related]
10. Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors.
Stock S; Benmebarek MR; Kluever AK; Darowski D; Jost C; Stubenrauch KG; Benz J; Freimoser-Grundschober A; Moessner E; Umana P; Subklewe M; Endres S; Klein C; Kobold S
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35902133
[TBL] [Abstract][Full Text] [Related]
11. Stromal depletion by TALEN-edited universal hypoimmunogenic FAP-CAR T cells enables infiltration and anti-tumor cytotoxicity of tumor antigen-targeted CAR-T immunotherapy.
Das S; Valton J; Duchateau P; Poirot L
Front Immunol; 2023; 14():1172681. PubMed ID: 37251405
[TBL] [Abstract][Full Text] [Related]
12. Single-Cell Analysis of Target Antigens of CAR-T Reveals a Potential Landscape of "On-Target, Off-Tumor Toxicity".
Zhang Y; Li Y; Cao W; Wang F; Xie X; Li Y; Wang X; Guo R; Jiang Z; Guo R
Front Immunol; 2021; 12():799206. PubMed ID: 34975912
[TBL] [Abstract][Full Text] [Related]
13. Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma.
Pituch KC; Miska J; Krenciute G; Panek WK; Li G; Rodriguez-Cruz T; Wu M; Han Y; Lesniak MS; Gottschalk S; Balyasnikova IV
Mol Ther; 2018 Apr; 26(4):986-995. PubMed ID: 29503195
[TBL] [Abstract][Full Text] [Related]
14. The pericyte and stromal cell marker CD248 (endosialin) is required for efficient lymph node expansion.
Lax S; Hardie DL; Wilson A; Douglas MR; Anderson G; Huso D; Isacke CM; Buckley CD
Eur J Immunol; 2010 Jul; 40(7):1884-9. PubMed ID: 20432232
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of CAR-T cell activity against cholangiocarcinoma by simultaneous knockdown of six inhibitory membrane proteins.
Qiao Y; Chen J; Wang X; Yan S; Tan J; Xia B; Chen Y; Lin K; Zou F; Liu B; He X; Zhang Y; Zhang X; Zhang H; Wu X; Lu L
Cancer Commun (Lond); 2023 Jul; 43(7):788-807. PubMed ID: 37282786
[TBL] [Abstract][Full Text] [Related]
16. PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies.
Jie Y; Liu G; Feng L; Li Y; E M; Wu L; Li Y; Rong G; Li Y; Wei H; Gu A
Front Immunol; 2021; 12():665970. PubMed ID: 34475869
[TBL] [Abstract][Full Text] [Related]
17. Chimeric Antigen Receptor T Cells With Modified Interleukin-13 Preferentially Recognize IL13Rα2 and Suppress Malignant Glioma: A Preclinical Study.
Kim K; Gwak HS; Han N; Hong EK; Choi BK; Lee S; Choi S; Park JH; Seok JH; Jeon Y; Cho H; Lee SJ; Lee Y; Nam KT; Song SW
Front Immunol; 2021; 12():715000. PubMed ID: 34819930
[TBL] [Abstract][Full Text] [Related]
18. STING agonist promotes CAR T cell trafficking and persistence in breast cancer.
Xu N; Palmer DC; Robeson AC; Shou P; Bommiasamy H; Laurie SJ; Willis C; Dotti G; Vincent BG; Restifo NP; Serody JS
J Exp Med; 2021 Feb; 218(2):. PubMed ID: 33382402
[TBL] [Abstract][Full Text] [Related]
19. Targeting Protein Tyrosine Phosphatase 22 Does Not Enhance the Efficacy of Chimeric Antigen Receptor T Cells in Solid Tumors.
Du X; Darcy PK; Wiede F; Tiganis T
Mol Cell Biol; 2022 Mar; 42(3):e0044921. PubMed ID: 35041491
[TBL] [Abstract][Full Text] [Related]
20. Endosialin (Tem1) is a marker of tumor-associated myofibroblasts and tumor vessel-associated mural cells.
Christian S; Winkler R; Helfrich I; Boos AM; Besemfelder E; Schadendorf D; Augustin HG
Am J Pathol; 2008 Feb; 172(2):486-94. PubMed ID: 18187565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
